Renal Disease

Disease State Hub

Videos

Video

Video

The Management of Patients With Primary Hyperoxaluria

06/28/2024

James Matera, DO

In this video, James Matera, DO, discusses the management of patients with primary hyperoxaluria (PH), including dietary modifications, hepatic and/or kidney transplantation, RNA interference agents,...

06/28/2024

Research Summaries

Research Summary

Lumasiran Shows Efficacy, Plasma Oxalate Reductions for Patients With Primary Hyperoxaluria, Severe Renal Impairment at 24 Months

06/20/2024

Anthony Calabro, MA

In the ILLUMINATE-C trial, patients with advanced primary hyperoxaluria type 1 and severe renal impairment treated with lumasiran showed decreased plasma oxalate and good safety profiles at 6 months and 12...

06/20/2024

FDA ALERT

FDA Approves Nedosiran for Patients 9 Years of Age and Older With Primary Hyperoxaluria Type 1

01/29/2024

Anthony Calabro, MA

The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.

01/29/2024

Endocrinology

FDA Approves New Drug for Cushing Disease

03/09/2020

The new treatment is the first FDA-approved drug to address the overproduction of cortisol in Cushing disease by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.

03/09/2020

Renal Disease

Model Predicts ESLD Among Patients with HIV

03/08/2019

A predictive model could be used to help risk of end-stage liver disease in people living with HIV, according to recent research.

03/08/2019

Kidney Disease

Childhood Kidney Disease May Raise Adulthood ESRD Risk

02/01/2018

The authors of a new study investigated the long-term risk for adulthood end-stage renal disease among individuals who had childhood kidney disease that resolved prior to adolescence.

02/01/2018

October 2024

Current Issue

October 2024

Volume 64

Issue 9